Donate

News

 

Next PBAC Meeting

Your chance to help

The following treatments for lymphoma will be
considered at the next Pharmaceutical Benefits Advisory Committee (PBAC)
meeting in November for consideration for inclusion on the Pharmaceutical
Benefits Scheme. (PBS)

OBINUTUZUMAB – (Gazyva) for follicular
lymphoma

BRENTUXIMAB VEDOTIN – (Adecetris) for Hodgkin
Lymphoma

IBRUTINIB – for Mantle Cell Lymphoma

ROMIDEPSIN – for PTCL

VORINOSTAT – for CTCL

Patients, family members, health care organisations, clinicians, researchers and other stakeholders are welcome to provide feedback to PBAC via their online portal. Please don’t underestimate the value of your feedback  

http://www.health.gov.au/internet/main/publishing.nsf/Content/PBAC_online_submission_form

The CLOSING date is the 5th of October, 2016. Patients and carers
will have the opportunity to complete the Lymphoma Australia survey for Gazyva,
Adecetris and Ibrutinib after World Lymphoma Day.

Share This
Cart
Checkout - $0.00
  • 0
  • 1

Contact Lymphoma Australia Today!

Patient Support Hotline

General Enquiries

Please note: Lymphoma Australia staff are only able to reply to emails sent in English language.

For people living in Australia, we can offer a phone translation service. Have your nurse or English speaking relative call us to arrange this.

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.